Emerging role of GLP-1 receptor agonists in the treatment of obesity

por Neff, Lisa M, Kushner, Robert F
Publicado 2010

Using psycho‐behavioral phenotyping for overweight and obesity: Confirmation of the 6 factor questionnaire

por Kushner, Robert F., Hammond, Michael M.
Publicado 2021

Development of a telehealth obesity OSCE and reliable checklist for assessment of resident physicians: a pilot study

por Cameron, Natalie A., Kushner, Robert F.
Publicado 2022

Physician counseling of young adults with rapid weight gain: a retrospective cohort study

por Tang, Joyce W, Kushner, Robert F, Thompson, Jason, Baker, David W
Publicado 2010

An obesity educational intervention for medical students addressing weight bias and communication skills using standardized patients

por Kushner, Robert F, Zeiss, Dinah M, Feinglass, Joseph M, Yelen, Marsha
Publicado 2014

Low priority of obesity education leads to lack of medical students’ preparedness to effectively treat patients with obesity: results from the U.S. medical school obesity education...

por Butsch, W. Scott, Kushner, Robert F., Alford, Susan, Smolarz, B. Gabriel
Publicado 2020

Development and outcomes of an immersive obesity summit workshop for medical resident and fellow education

por Velazquez, Amanda, Robinson, Katie J. H., Frederick, Jennifer L., Kushner, Robert F.
Publicado 2019

South Asian American Perspectives on Overweight, Obesity, and the Relationship Between Weight and Health

por Tang, Joyce W., Mason, Maryann, Kushner, Robert F., Tirodkar, Manasi A., Khurana, Neerja, Kandula, Namratha R.
Publicado 2012

What Matters in Weight Loss? An In-Depth Analysis of Self-Monitoring

por Painter, Stefanie Lynn, Ahmed, Rezwan, Hill, James O, Kushner, Robert F, Lindquist, Richard, Brunning, Scott, Margulies, Amy
Publicado 2017

Expert Coaching in Weight Loss: Retrospective Analysis

por Painter, Stefanie Lynn, Ahmed, Rezwan, Kushner, Robert F, Hill, James O, Lindquist, Richard, Brunning, Scott, Margulies, Amy
Publicado 2018

Diagnosing Obesity as a First Step to Weight Loss: An Observational Study

por Ciemins, Elizabeth L., Joshi, Vaishali, Cuddeback, John K., Kushner, Robert F., Horn, Deborah B., Garvey, W. Timothy
Publicado 2020

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

por Kosiborod, Mikhail N., Bhatta, Meena, Davies, Melanie, Deanfield, John E., Garvey, W. Timothy, Khalid, Usman, Kushner, Robert, Rubino, Domenica M., Zeuthen, Niels, Verma, Subodh
Publicado 2022

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, pla...

por Verma, Subodh, Bhatta, Meena, Davies, Melanie, Deanfield, John E., Garvey, W. Timothy, Jensen, Camilla, Kandler, Kristian, Kushner, Robert F., Rubino, Domenica M., Kosiborod, Mikhail N.
Publicado 2022

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

por O'Neil, Patrick M., Aroda, Vanita R., Astrup, Arne, Kushner, Robert, Lau, David C. W., Wadden, Thomas A., Brett, Jason, Cancino, Ana‐Paula, Wilding, John P. H.
Publicado 2017

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

por Kushner, Robert F, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Lim, Soo, Lingvay, Ildiko, Mosenzon, Ofri, Wallenstein, Signe O R, Wadden, Thomas A, le Roux, Carel W
Publicado 2021

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

por Mosenzon, Ofri, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Kushner, Robert F, Lim, Soo, Lingvay, Ildiko, Wallenstein, Signe O R, Wadden, Thomas A, Le Roux, Carel W
Publicado 2021

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

por le Roux, Carel W., Zhang, Shuyu, Aronne, Louis J., Kushner, Robert F., Chao, Ariana M., Machineni, Sriram, Dunn, Julia, Chigutsa, Farai B., Ahmad, Nadia N., Bunck, Mathijs C.
Publicado 2022

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

por Wadden, Thomas A., Chao, Ariana M., Machineni, Sriram, Kushner, Robert, Ard, Jamy, Srivastava, Gitanjali, Halpern, Bruno, Zhang, Shuyu, Chen, Jiaxun, Bunck, Mathijs C., Ahmad, Nadia N., Forrester, Tammy
Publicado 2023

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

por Kushner, Robert F., Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Garvey, W. Timothy, Goldman, Bryan, Lingvay, Ildiko, Thomsen, Mette, Wadden, Thomas A., Wharton, Sean, Wilding, John P.H., Rubino, Domenica
Publicado 2020

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)

por Suresh, Swaroop H, Kushner, Robert F, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Lim, Soo, Lingway, Ildiko, Wallenstein, Ofri Mosenzon Signe O R, Wadden, Thomas A, Roux, Carel W Le
Publicado 2022